文献速递介入腹部DSACT

经皮经腹与经食管胃减压导管姑息治疗恶性肠梗阻的安全性与有效性

Safety and efficacy of percutaneous transabdominal and transesophageal decompression gastric catheters for palliation of malignant bowel obstruction.
PubMed 文献 · Abdom Radiol (NY) · 2021-05-17

单中心回顾性研究纳入385例恶性肠梗阻患者,尝试经皮经腹胃造瘘(PTAG)或经皮经食管胃(PTEG)导管置入减压。PTAG技术成功率95.5%,PTEG 97.6%,并发症发生率分别为13.9%和22.5%(P=0.16)。合并腹水亚组PTAG成功率94.8%,并发症率12.9%。结论认为两种路径均成功率高、并发症低。

要点

  • PTAG与PTEG导管置入减压技术成功率高(>95%),并发症发生率低。
  • 合并腹水的MBO患者行PTAG仍安全有效,成功率94.8%。
  • PTEG并发症率22.5%略高于PTAG的13.9%,但差异无统计学意义(P=0.16)。

核心结论

  • 经皮经腹或经食管胃减压导管置入治疗恶性肠梗阻成功率高、并发症低,合并腹水患者行PTAG亦安全有效。

研究设计与样本

  • 单中心回顾性研究,2013年3月至2018年8月共385例恶性肠梗阻患者,尝试置入394根减压胃造瘘导管(PTAG 353根,PTEG 41根),参考标准为医疗记录和影像学检查。

诊断标准与关键数值

  • PTAG技术成功率95.5%(337/353),PTEG成功率97.6%(40/41)。
  • PTAG并发症涉及47例(13.9%),PTEG并发症涉及9例(22.5%),P=0.16。
  • 合并腹水亚组PTAG成功率94.8%(182/192),并发症涉及17例(12.9%)。

临床应用与阅片要点

  • 对恶性肠梗阻需胃减压者,可优先考虑PTAG,尤其合并腹水时仍可安全施行。
  • PTEG可作为替代路径,但需注意并发症率可能较高。

局限性

  • 单中心回顾性设计,可能存在选择偏倚和信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the safety and primary technical success rate of gastric decompression via percutaneous transabdominal gastrostomy (PTAG) or percutaneous transesophageal gastric (PTEG) catheter placement for management of malignant bowel obstruction (MBO). A secondary purpose was to evaluate the safety and success rate for PTAG catheter placement in patients with both MBO and ascites.

METHODS: A single-institution retrospective review of 385 patients who underwent attempted decompression gastric catheter placement from March 2013 to August 2018 was performed. Medical records and imaging studies were reviewed. A subgroup of patients with concomitant MBO and ascites were identified. The primary outcome measures were procedural technical success and procedural complications.

RESULTS: 394 decompression gastrostomy catheters were attempted from 2013 to 2018, n = 353 PTAG and n = 41 PTEG. The success rate was 95.5% (n = 337 of 353) for PTAG and 97.6% (n = 40 of 41) for PTEG. There were 63 total complications involving 47 (13.9%) patients following PTAG and 13 total complications involving 9 (22.5%) patients following PTEG, P = 0.16. For the subgroup of patients with MBO and ascites, the success rate was 94.8% (n = 182 of 192 patients), and there were 20 complications involving 17 (12.9%) of 132 patients.

CONCLUSION: Gastric decompression for patients with MBO via PTAG or PTEG catheter placement is associated with high success rates and low complications.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Litwin RJ, Tam AL, Sheth RA, et al. Safety and efficacy of percutaneous transabdominal and transesophageal decompression gastric catheters for palliation of malignant bowel obstruction. Abdom Radiol (NY). 2021. PMID: 33999283. doi:10.1007/s00261-021-03115-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。